Nigeria

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in young children. Two preventive interventions for RSV—a maternal vaccine and long-acting monoclonal antibodies (mAbs) delivered to infants—are recommended by the World Health Organization. When countries consider introducing new vaccines, immunization program cost and affordability are key questions.To address some of these questions, the University Medical Centre Utrecht and PATH conducted studies as part of a multi-country collaboration called the RSV GOLD III-Health Economics Study to evaluate the economic burden of RSV disease (or cost of illness) and the impact and cost-effectiveness of RSV prevention (e.g., via maternal immunization or long-acting monoclonal antibodies) in Gavi, the Vaccine Alliance-eligible countries. The estimates will help inform policy decisions in low- and middle-income countries where maternal immunization-preventable diseases often hit hardest.Find here links to the peer-reviewed journal articles and select fact sheets summarizing the research. [Note: Some publications and fact sheets are forthcoming.]

The Rotary Healthy Communities Challenge (RHCC) project is supporting community health workers (CHWs) in Nigeria, the Democratic Republic of the Congo, Zambia, and Mozambique to implement integrated community case management in their communities. Integrated community case management is a globally recognized strategy to equip CHWs with the training and tools to diagnose, treat, and refer cases of malaria, pneumonia, and diarrhea.In the flow charts below, learn about the selection, training, and deployment process for CHWs in each country to implement integrated community case management.

The Rotary Healthy Communities Challenge (RHCC) equips volunteers with tools and training to combat malaria, pneumonia, and diarrhea in Nigeria.

The Rotary Healthy Communities Challenge is a three-year project implementing integrated community case management (iCCM) in Nigeria, the Democratic Republic of the Congo, Mozambique, and Zambia. Community health workers, trusted individuals who are chosen by their own communities, are essential to successful iCCM and service delivery. The Rotary Healthy Communities Challenge is supporting community health workers in Nigeria through validation, trainings, and supportive supervision.

Integrated community case management (iCCM) is a globally recognized strategy to equip community health workers with the training and tools to diagnose, treat, and refer cases for malaria, pneumonia, and diarrhea. The goal is to increase access to health care and to improve outcomes for children under the age of five in hard-to-reach areas.With support from The Rotary International Foundation, The Gates Foundation, and World Vision, the Rotary Healthy Communities Challenge is expanding iCCM to project areas in Nigeria, the Democratic Republic of the Congo, Mozambique, and Zambia.The factsheet provides an overview of the Rotary Healthy Communities Challenge project.

PATH's Living Labs expands to the most populous state in Nigeria, where its human-centered design approach will be applied to reach more zero-dose children.

Effective cold chain equipment (CCE) is the backbone of successful vaccine delivery, but its seamless operation relies on a complex web of “behind-the-scenes” activities. This graphic, produced in collaboration between PATH, JSI, and Village Reach, highlights several crucial activities that are currently being implemented to contribute to robust CCE maintenance systems in multiple countries, such as Nigeria, Kenya, Ethiopia, and Tanzania. While not exhaustive, the activities presented here aim to inspire and inform other countries as we collectively strive to strengthen CCE maintenance globally, ultimately ensuring that lifesaving vaccines reach every person in need.

In 2017, African leaders made a historic commitment to improving access to lifesaving vaccines across the African continent by endorsing the Addis Declaration on Immunization (ADI). This pledge included a targeted goal to expand domestic investments, ensuring that every African benefits from immunization.The Africa Centers for Disease Control and Prevention (CDC) and the African Union Commission conducted a comprehensive review of the ADI to assess the implementation progress of the ten ADI commitments between 2017 and 2023, highlighting areas of slow advancement and disparities in progress among African Union member states. To corroborate this review, findings from a retrospective study, conducted by PATH’s Center for Advocacy and Policy, in nine African countries on immunization financing between 2017 and 2023, provided additional evidence—especially on the fluctuating trends in government financing for immunization.The following immunization advocacy resources include an overview Africa brief, and country-specific briefs that provide key findings and recommendations from the study and highlight common trends, challenges, and opportunities.

Chronic hepatitis B is commonly the result of vertical transmission, and babies who are infected before they are one year old have a 90% risk of developing chronic hepatitis. Yet when administered within 24 hours of birth, the hepatitis B birth dose vaccine can prevent 75% to 95% of vertical transmission.With funding from Gavi, the Vaccine Alliance, PATH is employing a mixed methods approach to assess learning questions on the feasibility, acceptability, cost, market access, and impact of innovative strategies to improve the reach of timely hepatitis B birth dose vaccine for babies born in both in- and out-of-facility settings.By exploring innovative delivery strategies, assessing the role of community health systems, and understanding stakeholder perspectives, the project’s primary objective is to identify effective models for increasing hepatitis B birth dose coverage. Evidence and insights from this initiative will be applicable to countries planning for hepatitis B birth dose vaccine introduction as well as those seeking to deploy new strategies to increase coverage rates and timely administration within 24 hours of birth.

PATH awards two organizations in Ethiopia and Nigeria to expand our Living Labs model.